Figure 5. Deletion of CD148 on hematopoietic and endothelial cells does not attenuate AHR.

(A) Flow cytometry plot showing deletion efficiency of CD148 gated on B220⁺ B cells of WT, WT Vav-Cre, Ptprj^TM–/TM–, and Ptprj^{TM–fl/TM–};Vav-Cre mice. Mice of the indicated genotypes were immunized and intranasally challenged with OVA or saline (B–E). (B) Pulmonary resistance measurements after intravenous administration of increasing doses of ACh in control (WT), Ptprj^TM+/TM–, Ptprj^{TM–fl/TM–}, and Ptprj^{TM–fl/TM–};Vav-Cre mice of the C57BL/6 strain. (C) BAL cell counts of total cells, macrophages, eosinophils, lymphocytes, and neutrophils of WT Vav-Cre, Ptprj^{TM–fl/TM–}, and Ptprj^{TM–fl/TM–};Vav-Cre mice. (D) Histologic scoring by a blinded observer of H&E staining (left panel) and PAS staining of lung sections (right panel) in WT Vav-Cre, Ptprj^{TM–fl/TM–}, and Ptprj^{TM–fl/TM–};Vav-Cre mice. (E) Relative OVA-specific serum IgE levels measured by ELISA in WT Vav-Cre, Ptprj^{TM–fl/TM–}, and Ptprj^{TM–fl/TM–};Vav-Cre mice. Data for all panels show the means ± SEM, with 8 to 15 animals per group. *P < 0.05, 2-tailed Student’s t test.